Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1416238 | 0.79 | RAB9A (0.39) | CYP2A6NOTUMNPC1RAB9AALDH1A1 | |
| SCHEMBL194158 | 0.76 | — | — | |
| SCHEMBL3512283 | 0.75 | EGLN2 (0.39) | PIK3CD | |
| SCHEMBL1417061 | 0.74 | AHR (0.46) | NOTUMNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL1724662 | 0.74 | MKNK1 (0.46) | PIK3CDCYP2A6ERN1 | |
| SCHEMBL2752723 | 0.73 | KDM1A (0.39) | — | |
| SCHEMBL1662273 | 0.72 | PIK3CD (0.73) | PIK3CDCYP2A6NOTUMNPC1RAB9A | |
| SCHEMBL196791 | 0.72 | KDM4E (0.30) | KDM4ECYP1A2 | |
| SCHEMBL7954169 | 0.71 | CYP11B1 (0.39) | PTGS2CHRNB2CHRNA4CHRNA7CHRNA3 | |
| SCHEMBL998693 | 0.71 | ATM (0.37) | CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351553-B2 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-08 | — | — | US | disclosed |
| US-12202797-B2 | Method for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20230322669-A1 | METHOD FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| EP-4257577-A2 | METHOD FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2023-10-11 | — | — | EP | disclosed |
| US-11649206-B2 | Method for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-16 | — | — | US | disclosed |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-23 | — | — | US | disclosed |
| US-11498898-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-11-15 | — | — | US | disclosed |
| EP-3929187-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-12-29 | — | — | EP | disclosed |
| US-20210309609-A1 | METHOD FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | US | disclosed |
| US-11066362-B2 | Method for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-20 | — | — | US | disclosed |
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-2309985-A2 | PHARMACEUTICAL COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2011-04-20 | — | — | EP | disclosed |
| EP-1919865-B1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010013823-A2 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | WO | disclosed |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090143444-A1 | ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| US-7498337-B2 | Acid secretion inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-03 | — | — | US | disclosed |
| EP-1919865-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2008-05-14 | — | — | EP | disclosed |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| WO-2007026916-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143444-A1 | ACID SECRETION INHIBITOR | HRH2, VIP, CCKBR | PIK3CD 3037/4885CYP2A6 833/4885NOTUM 460/4885 |
| US-11066362-B2 | Method for producing pyrrole compound | HPD, PPOX, CBR3 | PIK3CD 2899/4885CYP2A6 437/4885NOTUM 724/4885 |
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, MLST8, CYP3A43 | PIK3CD 671/4885CYP2A6 84/4885NOTUM 561/4885 |
| US-12351553-B2 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation | CYP51A1, PAH, HPD | PIK3CD 1310/4885CYP2A6 49/4885NOTUM 89/4885 |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | HRH2, ASNS, GHSR | PIK3CD 2279/4885CYP2A6 859/4885NOTUM 268/4885 |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | HRH2, GIPR, HRH4 | PIK3CD 1431/4885CYP2A6 1525/4885NOTUM 2294/4885 |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | PIK3CD 1889/4885CYP2A6 46/4885NOTUM 62/4885 |
| US-11498898-B2 | Process for producing pyrrole compound | DHPS, STS, HPD | PIK3CD 1889/4885CYP2A6 46/4885NOTUM 62/4885 |
| US-12202797-B2 | Method for producing pyrrole compound | HPD, PPOX, CBR3 | PIK3CD 2899/4885CYP2A6 437/4885NOTUM 724/4885 |
| US-20210309609-A1 | METHOD FOR PRODUCING PYRROLE COMPOUND | HPD, PPOX, CBR3 | PIK3CD 2899/4885CYP2A6 437/4885NOTUM 724/4885 |
| US-20230322669-A1 | METHOD FOR PRODUCING PYRROLE COMPOUND | HPD, PPOX, CBR3 | PIK3CD 2899/4885CYP2A6 437/4885NOTUM 724/4885 |
| US-11649206-B2 | Method for producing pyrrole compound | HPD, PPOX, CBR3 | PIK3CD 2899/4885CYP2A6 437/4885NOTUM 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.